The present disclosure relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The disclosure also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The disclosure also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The disclosure also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present disclosure also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The disclosure also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The disclosure also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present disclosure.本發明係有關於可與M-CSF(較佳為人類M-CSF)行特異性結合並發生抑制M-CSF作用之抗體及其抗原結合部分。本發明亦有關人類抗-M-CSF之抗體及其抗原結合部分。本發明亦有關於抗體，其可為嵌合型、雙特異性(bispecific)、經衍生之單鏈抗體或融合蛋白之部分。本發明亦有關於起源自人類抗-M-CSF抗體之分離的重鏈及輕鏈免疫球蛋白及可編碼此種免疫球蛋白之核酸分子。本發明亦有關於製備人類抗-M-CSF抗體之方法、包括這些抗體之組合物及使用該抗體與組合物供診斷及治療的方法。本發明亦提供使用可編碼重鏈及/或輕鏈免疫球蛋白分子之核酸分子的基因療法，其中該免疫球蛋白包括人類抗-M-CSF抗體。本發明亦有關於包括本發明核酸分子之基因轉殖動物及基因轉殖植物。
